NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and Other Influenza Viruses. Geneva: World Health Organization; 2010 Feb.
WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and Other Influenza Viruses.
Show detailsThe standard doses for oseltamivir and zanamivir are based on clinical studies in outpatient settings, and with uncomplicated influenza virus infection. Doses for management of severe or complicated illness are discussed within these recommendations. Specific recommendations have also been made for doses for young children, infants and neonates. Further information is also provided in the Prescribing Information and Summary of Product Characteristics for each product.
As a reference, the standard adults doses, as given in Summary of Product Characteristics, for each product are provided below:
Oseltamivir
Oseltamivir is indicated for treatment of patients one year of age and older.
For adolescents (13 to 17 years of age) and adults the recommended oral dose (based on data from studies in typical uncomplicated influenza) is 75 mg oseltamivir twice daily for 5 days.
Zanamivir
Zanamivir is indicated for treatment of influenza in adults and children (>5 years).
The recommended dose for treatment of adults and children from the age of 5 years (based on data from studies in typical uncomplicated influenza) is two inhalations ( i.e. 2 × 5mg) twice daily for 5 days.
- Table of standard dosages - WHO Guidelines for Pharmacological Management of Pan...Table of standard dosages - WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and Other Influenza Viruses
Your browsing activity is empty.
Activity recording is turned off.
See more...